BridgeBio Oncology Therapeutics (NasdaqGM:BBOT) FY Conference January 12, 2026 08:15 PM ET Company ParticipantsNone - Company Representative 2Pedro Beltran - Chief Scientific OfficerEli Wallace - CEONone - Company Representative 1Conference Call ParticipantsNone - AnalystEli WallaceVery well for key data sets later this year. To summarize the findings that I'll share in subsequent slides, 8520, the first direct KRAS G12C on-off inhibitor, the data we've generated, and I'll cover it subsequently, positions i ...